Skip to main content

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The BLISS-LN trial

This BLISS-LN trial demonstrated the potential of belimumab as an add-on therapy for patients with lupus nephritis; lead investigator Richard Furie discusses why these findings are important for this patient population (8:28).

Read the transcript

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Image Credits